Our Resident Network
Meet Our Residents
LabCentral has generated significant interest from entrepreneurs and startups working on groundbreaking science who are eager to join LabCentral, a first-of-its-kind, fully resourced and equipped life-sciences laboratory space. Participants are chosen through a competitive process, where only the highest-potential applicants are selected in keeping with our mission.
Empowering patients to combat cancer
and preserve their quality of life.
Redefining drug delivery with on-target, sustained therapy using thermogelling polymers.
Absco Therapeutics unlocks the full potential of immune-modulating therapies using thermogelling polymers that transform from liquid to solid at body temperature, holding position on injection to create controlled-release drug depots optimal for immune education.
RNA medicines to treat, delay, and prevent diseases of the brain.
Targeted delivery of RNA medicines to the brain. By silencing the genes that cause harm, we aim to preserve minds, protect memories, and enable our loved ones to live healthier, longer lives.
Built on three pillars
- Next-generation RNA medicines
- Systemic administration and targeted brain delivery
- Precision and prevention to transform CNS treatment
Delivering therapeutics where the body needs them.
Directing a drug to the exact tissue that needs it is one of the hardest problems in medicine. We're solving it by decoding the body's glycan code — the sugar-based signatures unique to every tissue. Through high-throughput in silico and in vivo screening, we map tissue glycan signatures at cellular resolution and design peptides that recognize them.
Beyond Known Biology
The future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how.
Basecamp Research trains frontier AI models for therapeutic design. Our EDEN models are trained on BaseData, the world’s largest proprietary evolutionary genomic dataset: over 100 billion novel genes sourced through partnerships in more than 30 countries across all seven continents. We are now rapidly advancing a pipeline of EDEN-designed therapeutics towards clinical development. Headquartered in London, we have offices and labs in Boston.
Accelerate insights by connecting phenotype to genotype.
The Bifrost platform connects single-cell phenotypes including morphology, protein localization and production, cellular responses, and cell-cell interactions to underlying alleles at massive scale. Integrated software allows rapid progression from experiment to massive multi-parameter dataset to actionable insights.
BioFeyn’s goal is to produce the most sustainable and nutrient-packed protein on the market.
BioFeyn is a life sciences company, applying biomedical technology to make exponential advancements in food systems and sustainability. By working with leaders in aquaculture, agriculture, and cell culture, we’re enabling new solutions to improve both the health of people and the planet.
Decoding the human protein interactome for safer, more targeted therapies.
95% of approved medicines target proteins as isolated entities, bluntly turning them on or off. This modulates protein function globally, across pathogenic and healthy cellular pathways. It’s why essentially all medicines come with side effects. We target protein interactions. By targeting protein-protein interactions (PPIs), we aim to modulate only the pathogenic pathway, leaving healthy functions intact.
A Next Generation Approach To Healing
We offer a next-generation collagen platform that enables precise, injectable delivery of complete human collagen—advancing beyond first-generation therapeutics to enable rapid, effective healing. Our proprietary manufacturing and targeting approach represents a breakthrough in musculoskeletal injury treatment and wound repair.
We discover molecules where biology actually happens.
Bullseye uses directed evolution inside living cells to discover functional molecules against challenging intracellular targets.
Rather than starting with a predefined mechanism or simplified assay, we generate and evaluate molecular diversity directly in cells, selecting for the biological outcome that matters.
While ASO therapeutics have been shown to be effective at treating disease by targeting disease genes at the RNA level intracellularly with long tissue resident half-life, they have been limited in their ability to treat neurological disease as they cannot effectively get across the blood brain barrier.
Centron Bio is transforming the treatment of neurological disorders with genetic medicines that cross the blood brain barrier.
Cha Therapeutics Inc. is an early-stage, privately held, Massachusetts-based biotechnology start-up developing a proprietary epigenetic therapy that improves cancer patient outcomes.
Our mission is to develop groundbreaking drug combinations to treat cancers that have evaded the immune system, particularly those driven by Wnt signaling.
Our unique approach leverages a combination of compounds designed to re-program tumor cells, making them more susceptible to immune checkpoint inhibitors and other immunotherapies.
Unlocking the full potential
of RNA medicine.
Collage Bio is developing a new class of programmable RNA therapeutics. Our platform combines AI-powered design with advanced polynucleotide engineering to enable precise, durable, and tunable control of gene expression. By bridging gene editing and traditional RNA approaches, we are opening a new frontier in programmable medicine.
Conveyor therapeutics aims to be the first company dedicated to expanding the knowledge of ADC design and development to novel payloads, targeting antigens, and indications. We seek to merge people, passion, and science to create therapeutics, which modulate intracellular targets with cellular precision, to restore health and save lives.
Pioneering ATP-assembled conditional biologics for the treatment of cancer.
Extracellular adenosine triphosphate (eATP) is highly elevated in solid tumors making it a hallmark of cancers. Relative to normal tissue, tumors release eATP at high levels to help them develop and grow.
Crosslink has engineered a modular biologic domain which takes advantage of this difference to assemble therapeutics in tumors. Crosslink’s domain can be applied to virtually any therapeutic modality to improve tumor specific targeting and enhanced activity. We are currently focused on developing first-in-class/best-in-class applications in antibody drug conjugates and radioligand therapies.
Developing therapies to halt the progression of neurodegenerative disease.
Our target and drug discovery platform is designed to recapitulate key aspects of human neurodegenerative biology by combining four integrated systems:
Analytics: Derive new biological insights from small and sparse data sets.
Network Biology: Map progression-associated signals to prioritize disease drivers.
Human iPS Cells: Recapitulate progression in vitro with a complex system that includes mature, aged cells.
Chemistry & Screening: Mechanism-linked phenotypic assays to go from target to lead.
Leading Beyond Chemistry
Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise.
The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025.
The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.
The future of biologics is genetic code expansion.
Any synthetic amino acid. Any protein. Any size.
Reshaping immunity through precision therapeutics.
Our aim is to develop a novel domain for immune recruitment for bispecific T cell engagers that specifically recruits immune cells in an activated, cytotoxic state. To do this, we are designing therapeutics that mimic antigens from common infectious diseases. In effect, our therapeutics will direct potent, existing immune responses for an infectious disease (e.g. SARS-CoV-2, influenza) towards a cancer, leading to a more precise and efficacious response.
Cell Therapy Meets Unprecedented Scalability
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.
GelMEDIX is developing therapies that restore vision loss by regenerating damaged retinal cells and preserving the essential structures required for sight.
Our groundbreaking biomaterials technology has unlocked a new approach to optimize the delivery, efficacy, and safety of cell and gene therapies. GelMEDIX programs are based on our proprietary injectable hydrogel scaffold that we have engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies.
Our team combines deep expertise in biomaterials engineering, regenerative medicine, and ophthalmology with this technology platform to develop vision-restoring therapies that overcome the limitations of current cell therapy approaches. We believe our approach opens a new frontier for the development of treatments with the potential to restore vision in patients who currently have limited or no options.
A New Generation of Therapeutics. Harnessing the power of synthetic biology, protein engineering and cell-protective physiology.
General Biologics, Inc. uses the power of rational biological design to create new classes of therapeutics for treatment of unmet medical needs that have been underserved by the research community and overlooked by investors.
We have used this approach to develop a ground-breaking, first-in-class fusion protein therapeutic for treatment of hypoxia.
Curing genetic and age-associated diseases.
HarborSite’s targeted gene insertion platform enables precise and efficient integration of therapeutic genes into safe genomic sites, creating the potential for one-time, durable treatments across thousands of genetic diseases and age-related disorders with a single intervention.
Accessible Gene Therapy for Liver Diseases.
HydroGene has a mission to bring gene therapy to all liver diseases. This can be accomplished with non-viral gene delivery, which would be safe, cheap, and redosable. Unfortunately, non-viral gene delivery with lipid nanoparticles has suffered of inefficiency from nuclear delivery of DNA cargo.
As an alternative, HydroGene has solved how to scale hydrodynamic delivery inot the liver of large animals for the first time by leveraging the biliary system. HydroGene's approach is efficient, scalable, and safe in porcine and primate models and has exciting potential to treat rare and common diseases.
InGel Tx technology is an injectable biomimetic hydrogel platform engineered for the sustained release of stem cells and drugs in the eye, initially targeting regenerative medicine for retinitis pigmentosa, macular degeneration and geographic atrophy.
Research Area:
Biological Product
Cell Therapy
Interacta is building the data layer for AI native antibody discovery. While language and vision AI thrive on massive datasets biology is still operating with fewer than 15000 antibody antigen interactions. We are fixing that. Our platform screens over 100 million interactions per week in mammalian cells with functional relevance and at one thousandth the traditional cost.
This is not a CRO. It is a new operating model high quality non exclusive binder datasets across diverse targets ready to fine tune AI models or jumpstart discovery campaigns. We are doing for antibodies what Scale AI did for language and vision fueling the next generation of in silico biology.
Interon Laboratories is developing a new category of immunotherapy:
neuro-immunotherapy. Interon's exclusive technology brings together neurobiology and immunology, and is novel and non-invasive. This revolutionary science includes discoveries made by Interon's Co-Founders at MIT and Harvard Medical School, and was featured in journals including Nature, Science and Cell. Additionally, Interon has two lead programs to develop biologics and small molecule therapeutics for mitigating neurological and immune disorders.
Laurel is a preclinical biotechnology company developing next-generation antibody therapeutics for cardiovascular disease.
Our platform combines AI-enabled design with immune-derived discovery to generate modular single-domain and monoclonal formats that address crosstalk among cardiovascular, inflammatory, and metabolic pathways, with the goal of reducing patients’ at-home pharmacy burden.
Analyse single cell interactions and functional dynamics at scale.
We are developing a flexible platform that enables the direct, precise interrogation of single cell heterogeneity, interactions and functional behaviours. Across a broad range of disciplines from basic and translational research to drug discovery, we provide the freedom to accelerate discovery and apply novel biological insights.
Sparking immune regeneration via thymus regeneration.
1. Lightning Bio uses deep knowledge of immune cell generation and bioengineering to restore immunity damaged by toxins, disease, or age
2. Lightning Bio leverages the body's inherent regenerative capacity to create novel therapeutics for immune dysfunction
3. Lightning Bio's science works to replenish T cell diversity through modification of the body's cell factories
Medicines that Selectively Target Pathogenic T Cells
The pathogenic T cells that cause autoimmune diseases are a small fraction of the T cells in the immune system, but the harm they cause can be devastating. Today's autoimmune disease medicines are applied to the whole body instead of just these cells, and aren't safe or precise enough.
We are changing the way the world thinks about biomaterials.
Nearly 30% of surgical procedures still result in bleeding-related complications. Limax's hydrogel platform adheres strongly to wet, dynamic tissue — both inside and outside the body — with an adhesion and healing performance current sealants and sutures can't match. Our hydrogels are designed to solve real, unmet needs in surgery.
Coming Soon
Research Area:
Biological Product
Cell Therapy
Think outside the cell. Target the matrix.
Matrisome Bio is developing tools to deliver targeted therapies to the extracellular matrix (non-cellular components) of disease tissues such as tumors and fibrotic lesions in order to convert it from a barrier to a drug depot.
We're building curative genetic medicines for kidney and pancreatic diseases.
Nephrogen is a Stanford biotech spinout commercializing an AI screening platform to solve gene delivery for serious diseases. Delivery is the central bottleneck in genetic medicine. As of Q1 2026, there are 903 clinical-stage genetic medicines, but almost zero target the kidney or pancreas, a gap driven primarily by the lack of efficient delivery vehicles for reaching these tissues.
These improved delivery vehicles unlock curative genetic therapy for kidney and pancreatic diseases, which affect 1 in 7 Americans, account for a significant share of Medicare spending, and have no approved gene-based therapies today.
B7-H7 Broad impact. Precision Therapeutics.
NextPoint is launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing a T-cell engager engineered with superior therapeutic index, an antibody-drug-conjugate with our proprietary linker technology, and a multi-functional checkpoint inhibitor.
Nucyrna Therapeutics aims to establish a new paradigm of RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNA via one oligonucleotide drug.
Category Shifting Technology
Oddity Labs is a biotechnology research and development center to power Oddity product innovations through the discovery and development of molecules, probiotics, peptides, and other biological modalities. We are developing the world's most advanced phenotypic database to understand the biological mechanisms that drive cellular behavior for beauty and wellness indications.
Next-Generation Therapies. Pulsatile. Programmable.
We will be developing injectable microparticles containing drugs (vaccines, other API's) that have programmable release kinetics and time points. These microparticles provide self-boosting vaccines, replace multiple injections with a single injection, and also enable long term storage of drugs without the need for cold chain.
Orthrus is pioneering antigen-specific immune tolerance to treat autoimmune and allergic diseases at their root. Built on our proprietary Tolerance platform, we create nanobody-antigen-drug conjugates that retrain the immune system to ignore disease-driving antigens, without the need for broad immunosuppression. Unlike conventional therapies that only manage symptoms, Orthrus aims to deliver durable, disease-modifying treatments.
Overture Therapeutics is engineering antibody-based therapies that target the root causes of obesity, not just appetite.
Our programs act directly on adipose and muscle tissue to drive safer, more sustainable weight loss while preserving metabolic health, offering a differentiated alternative or complement to GLP-1 therapies.
Creating transformative medicines for people with inflammatory diseases.
At Promakhos, we utilize unique insights from patient samples to develop medicines that address the root cause of inflammatory diseases. Instead of blocking the immune system, our medicines aim to restore the natural ability of the body to manage inflammation and heal.
Advantage, engineered.
The world the mission operates in is going post-quantum, contested, and machine-speed. Quantum Sky engineers the advantage across cyber, networks, software, and quantum because the mission demands dominance, not parity. We don't follow the map. We draw it.
A New Genetic Logic for Cancer Therapy
Targeted therapies have transformed precision oncology, but they lack the long-term durability needed to cure advanced tumors. At Red Ace, we take a different approach: we reprogram tumors from the inside out to create entirely new therapeutic opportunities. By rewiring cancer cells with synthetic vulnerabilities, our platform can overcome resistance and enable treatments that last.
AI-Powered RNA-Targeting to Make Every Target Druggable
Riboway specializes in controlling how proteins are made by targeting RNA. Our smart RNA-targeting technology enables us to upregulate, downregulate, activate, or inhibit target proteins, depending on therapeutic needs. This flexibility is driven by our AI-based platform that decodes RNA regulation to identify druggable angles. So far, we’ve successfully validated 5 out of 5 targets attempted.
Transforming the Lives of Patients Living With Heart Failure
One in three patients living with heart failure has a monogenic mutation that drives disease. We are addressing genetic drivers of heart failure using targeted, non-viral gene-modulating therapies. Our vision is to transform the lives of millions with a portfolio of first-in-class disease-modifying medicines. Our team of life science professionals has decades of experience discovering and developing medicines for patients living with cardiovascular and genetic diseases.
Innovating Haircare Through Research Science
Positioned at the crossroads of science and beauty, Strand Research’s mission is to address the most significant challenges in hair care faced by consumers today. We develop novel compounds, including small molecules, peptides, and polymers, with a science-first approach, and are committed to innovation through data.
Synolo Therapeutics, an early-stage biotechnology company launched by RA Capital, is pioneering the development of precision-targeted immunotherapies for cancer. Powered by computational protein design and proprietary technologies which yield biological data sets at unprecedented scale and resolution, we are building a pipeline of first-in-class multi-specific biologics with novel functionalities. Synolo was founded by pioneers in the field of protein design and engineering, synthetic biology, DNA sequencing, immunology, and biologics drug discovery and development.
The Termeer Institute is a catalyst for innovation that brings life-changing treatments to patients worldwide.
We support and empower brilliant life science innovators through values-driven leadership programming including mentorship, network development and thought leadership to advance groundbreaking, patient-centric solutions.
Rewriting RNA’s regulatory code to disrupt tumor survival
For more than a decade, our research has mapped how RNA methylation governs cellular survival. That work uncovered a critical dependency in cancer cells on the demethylase FTO.
Today, Tinos Tx translates that insight into first-in-class small molecule inhibitors designed to destabilize tumor-driving RNA and collapse cancer from within.
Authoring a new chapter in durable genetic medicines for patients living with cancer and other life-threatening diseases.
An all-RNA platform that inserts full length therapeutic genes at a natural safe harbor site, with no double-strand breaks and no viral vector required
Immunogenic Cell Death for Cancer Therapy
At Viska Bio, we are pioneering a modular platform of novel fusion proteins designed to drive anti-tumor immunity by modulating and mimicking immune responses to immunogenic cell death (ICD). This adaptable approach engages both innate and adaptive immunity, expanding precision oncology beyond traditional targets to eliminate cancer and prevent recurrence.
We are building transformative cell & gene therapy ventures
We are biotech venture builders and drug developers with decades of experience in cell & gene therapies. We have created a novel model to unlock innovation in this transformative space, delivering life-saving treatments and making them accessible to patients worldwide.
